Balancing benefits and risks in the era of biologics

Giovanni Adami*, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guanabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet Geusens

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

2 Citations (Web of Science)

Abstract

Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.

Original languageEnglish
Article numberARTN 1759720X19883973
Number of pages6
JournalTherapeutic Advances in Musculoskeletal Disease
Volume11
DOIs
Publication statusPublished - Oct 2019

Keywords

  • benefit-risk ratio
  • biologics
  • denosumab
  • romosozumab
  • POSTMENOPAUSAL WOMEN
  • RHEUMATOID-ARTHRITIS
  • CERTOLIZUMAB PEGOL
  • ROMOSOZUMAB
  • PREVENTION
  • INFLIXIMAB
  • FRACTURES
  • DENOSUMAB
  • DISEASES
  • SAFETY

Cite this